Navigation Links
ROX Medical secures financing and achieves key milestones in providing minimally-invasive approach for treating hypertension
Date:9/6/2012

SAN CLEMENTE, Calif., Sept. 6, 2012 /PRNewswire/ -- ROX Medical announced the closing of a financing round totaling $6M.  The financing will be used to initiate an international trial of the ROX FLOW procedure for the treatment of resistant hypertension (high blood pressure). Previously, ROX has successfully evaluated the FLOW procedure in pilot studies:  "The very encouraging results from our pilot hypertension trial was the basis for this investment, enabling us to pursue a more comprehensive, randomized study using the FLOW procedure," said CEO Rodney Brenneman.

According to the Centers for Disease Control, 68 million people in the US have high blood pressure and 1.2 billion people worldwide.  Of those, 50% of patients experience hypertension that remains uncontrolled (blood pressure above 140/90) and 15-20% have resistant form of hypertension. According to the American Heart Association, a 5 mmHg reduction in systolic blood pressure results in a 14% decrease in stroke, a 9% decrease in heart disease and a 7% decrease in overall mortality. 

ROX Medical's FLOW procedure is a short, minimally invasive, catheter-based procedure whereby Interventional Cardiologists, Radiologists or Endovascular Specialists place a stent-like connection between the artery and vein in the upper leg. The procedure is intended to reduce peripheral vascular resistance, thereby holding the promise of a meaningful long-term reduction in hypertension.  Uniquely, the FLOW procedure only involves the vascular structure, has an immediate effect; and is fully reversible.

To-date, ROX Medical has raised approximately $50M for its FLOW system, initially for studies and early commercialization of the FLOW procedure for COPD (pulmonary) treatment. The prior successful studies on COPD patients also demonstrated a significant lowering of blood pressure in hypertensive patients. "Hypertension physicians were encouraged by this response in our COPD patients, and pushed us to pursue this therapy separately for resistant hypertension patients as well.  We're excited to move forward with a randomized controlled trial," Brenneman said. Pilot results with the ROX FLOW procedure in resistant hypertensive patients have shown reductions in systolic and diastolic blood pressure on par with those for device therapies like renal denervation.

The ROX FLOW procedure for hypertension is not approved for use in the U.S.

Investors in the latest round of funding include continuing investors Domain Associates and Versant Ventures.


'/>"/>
SOURCE ROX Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
2. Medical Alarm Retires Last of Convertible Preferred Stock
3. Concord Medical Responds to Unusual Market Activity in its Stock
4. International Spine Products Manufacturer Featured in Upcoming US Business Executive Publication - www.gsmedicalusa.com
5. Medical Alarm Provides Investor Update -- Company Surpassing Previous Record Order Levels as Consumer Interest Accelerates
6. MyEvaluations.com Launches New Medical Education Management Solutions That Meet ACGME NAS Accreditation Requirements
7. Fall Alert Announces Its New Medical Alert Systems Website
8. Surefire Medicals Infusion System For Embolization Procedures Receives CE Mark Approval
9. Magnalight Releases Handheld Infrared Light for Medical Applications
10. GHX Selects MicroStrategy to Offer Healthcare Suppliers Enhanced Access to Distributed Medical-Surgical Market Data
11. Sacred Heart Medical Center Deploys Talysts Pharmacy Automation for Inventory Control and Improved Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, ... dedicated to helping service members that have been wounded in battle and their families. ...
Breaking Medicine News(10 mins):